DexCom (NASDAQ: DXCM) is not a stock that investors should be rushing to sell. It has a few different opportunities to continue pursuing to generate growth, it has plenty of recurring revenue, and the ...

One underappreciated reason why I feel DXCM could potentially gain more favorable interest is because its long-suffering ...

What Happened? A number of stocks fell in the afternoon session after the February jobs report revealed an unexpected ...

Dexcom on Monday announced its new over-the-counter continuous glucose monitor Stelo is officially available for purchase in the U.S. Glucose is a type of sugar people receive from food, and it's the ...

But what if companies outside of the pharmaceutical industry benefit as well? One excellent candidate to do so is DexCom ...

Dexcom will stop producing G6 CGM sensors July 1, 2026, urging patients to switch to the smaller, more accurate G7 model.

It's been a tough year for DexCom (NASDAQ: DXCM), whose stock price is down 25% since the start of 2025. It's a surprising performance, given that the overall stock market has been doing well; you ...

DexCom is one of the leaders in an industry with massive growth potential. The company is building a competitive advantage. Despite several risks, it could deliver substantial returns in the long run.

Shares of medical device company DexCom (NASDAQ:DXCM) jumped 7.3% in the morning session after it reported ...

DexCom seems to be growing fairly consistently, and that could continue. But the competition for its segment is getting fiercer by the quarter. The long-term effect of new medicines could potentially ...

Medical device specialist DexCom (NASDAQ: DXCM) is going through a rough patch. The company's shares dropped off a cliff following its second-quarter earnings report. However, zooming out helps put ...